{"id":16152,"date":"2021-12-13T09:03:58","date_gmt":"2021-12-13T09:03:58","guid":{"rendered":"https:\/\/clinlabint.com\/?p=16152"},"modified":"2021-12-13T09:03:58","modified_gmt":"2021-12-13T09:03:58","slug":"scirhom-announces-changes-to-management-and-appointment-of-board-of-directors","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/scirhom-announces-changes-to-management-and-appointment-of-board-of-directors\/","title":{"rendered":"SciRhom announces changes to management and appointment of Board of Directors"},"content":{"rendered":"
\"Dr.

Dr. J\u00fcrgen Ree\u00df, Chief Medical Officer, SciRhom<\/p><\/div>\n

SciRhom GmbH, a therapeutic antibody developer, announced the addition of Dr. J\u00fcrgen Ree\u00df to the management team as Chief Medical Officer. At the same time, the company is strengthening its business and scientific strategy with the establishment of a Board of Directors. The three members of the Board, Prof. Carl Blobel, Dr. Wolfgang Baiker, and Mr. Hans-Ulrich Rabe, will be instrumental in steering the company along a successful path through the next phase of its development. In January 2022, Dr. Andreas Jenne, currently Chief Business Officer of SciRhom, will move from management and join the Board of Directors as a fourth member.<\/p>\n

SciRhom has taken critical steps in advancing their first-in-class antibodies against iRhom2 towards clinical development. Proof-of-principle studies demonstrated preclinical efficacy of the drug candidates in protecting mice against rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The antibodies suppress iRhom2, thereby inhibiting tumour necrosis factor-alpha-convertase (TACE; also known as ADAM17), which conversely blocks several disease-causing signalling pathways. Achievement of this milestone also marks the beginning of the next stage in product development and company progress.<\/p>\n

\u201cSciRhom is an agile enterprise,\u201d\u00a0explained Chief Executive Officer Dr. Jens Ruhe.\u00a0\u201cAs we move into this exciting new development phase, we\u2019ve fine-tuned company structures to ensure that our ranks include top expertise to guarantee successful outcomes. We are in an extraordinary position to have such renowned and experienced partners join our efforts. Each member of our management team and our Board of Directors plays an indispensable role in swiftly moving our innovative therapy concept from our labs to patients with debilitating autoimmune diseases.\u201d<\/p>\n

Dr. J\u00fcrgen Ree\u00df\u00a0joins the corporate management team to guide the continued evolution of the therapeutic product and coordinate the company\u2019s development pipelines focused on RA, IBD, and systemic lupus erythematosus glomerulonephritis. A trained physician with a medical and doctorate degree from the University of Ulm, Germany, Dr. Ree\u00df has been a longstanding leader in the pharmaceutical industry. He has supervised the development, approval, and launch of numerous major therapies across several therapy areas, most recently as Corporate Senior Vice President of International Project Management at Boehringer Ingelheim Human Pharma.<\/p>\n

The new Board of Directors will include SciRhom co-founder\u00a0Prof. Carl Blobel, whose groundbreaking research laid the scientific foundation of SciRhom\u2019s technology. Dr. Blobel is Professor of Medicine and of Physiology, Biophysics and Systems Biology at Weill Cornell Medicine, and Chairman of the Arthritis and Tissue Degeneration Program at the Hospital for Special Surgery in New York City. His in-depth knowledge of iRhom2 and TACE will guide the technological roadmap of the company and strengthen the scientific evolution of the product.<\/p>\n

The second Board member,\u00a0Dr. Wolfgang Baiker, is an internationally respected advisor and partner for multiple life science business projects. As Venture Partner at Wellington Partners Venture Fund, Dr. Baiker has leveraged his years-long experience as Board member and CEO of Boehringer Ingelheim USA to help rising companies establish themselves in an international market. He is also an investor in SciRhom. Dr. Baiker fulfils a key role in shaping the corporate strategy to grow SciRhom\u2019s organization and infrastructure.<\/p>\n

Hans-Ulrich Rabe\u00a0rounds off the new Board of Directors. A trusted advisor in strategic asset allocation and direct investment in high-potential biotech companies, Mr. Rabe represents a consortium of four private investors \u2013 SciRhom\u2019s largest investment group. With strong business acumen and extensive experience in mentoring companies and fostering their development, Mr. Rabe brings a wealth of expertise in logistics, risk assessment, and finance management to fortify the company\u2019s performance.<\/p>\n

Having successfully secured seed funding for SciRhom as the Chief Business Officer,\u00a0Dr. Andreas Jenne\u00a0will move from corporate management to the Board of Directors in January 2022. A co-founder of SciRhom, Dr. Jenne has comprehensive knowledge of the company. His appointment to the Board of Directors aligns with the transition of SciRhom from start-up to product-oriented enterprise.<\/p>\n","protected":false},"excerpt":{"rendered":"

SciRhom GmbH, a therapeutic antibody developer, announced the addition of Dr. J\u00fcrgen Ree\u00df to the management team as Chief Medical Officer. At the same time, the company is strengthening its business and scientific strategy with the establishment of a Board of Directors. The three members of the Board, Prof. Carl Blobel, Dr. Wolfgang Baiker, and […]<\/p>\n","protected":false},"author":3,"featured_media":16153,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-16152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/16152"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=16152"}],"version-history":[{"count":2,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/16152\/revisions"}],"predecessor-version":[{"id":16291,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/16152\/revisions\/16291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/16153"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=16152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=16152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=16152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}